Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
1786- MEL,    What is known about melatonin, chemotherapy and altered gene expression in breast cancer (Review)
- Review, NA, NA
AntiTum↑, Risk↓, ChemoSen↑,
1785- MEL,    Antitumoral melatonin-loaded nanostructured lipid carriers
- in-vitro, Var, NA
selectivity↑, TumCD↑,
1784- MEL,    Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials
- Review, NA, NA
Remission↑,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX↑, P21↑, p27↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
1781- MEL,    Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial
- Trial, Lung, NA
QoL↑, OS∅, selectivity↑,
1780- MEL,    Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing
- Review, Var, NA
*antiOx↑, *toxicity↓, ChemoSen↑, *eff↑, *mitResp↑, *ATP↑, *ROS↓, *CardioT↓, *GSH↑, *NOS2↓, *lipid-P↓, eff↑, *HO-1↑, *NRF2↑, *NF-kB↑, TumCP↓, eff↑, neuroP↑,
1779- MEL,    Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review
- Review, BC, NA
QoL↑, OS↑, Dose∅, antiOx↑, ROS↑, SOD↑, Catalase↑, GPx↑, Risk↓, NK cell↑, IL1β↓, IL6↓, TNF-α↓, radioP↑, chemoP↑, TumVol↓, TumMeta↓, angioG↓, ChemoSen↑, eff↑,
1778- MEL,    Melatonin: a well-documented antioxidant with conditional pro-oxidant actions
- Review, Var, NA - Review, AD, NA
*ROS↓, *antiOx↓, ROS↑, selectivity↑, Dose↑, *mitResp↑, *ATP↑, *ROS↓, eff↑, ROS↑, Dose↑, *toxicity∅, ROS↑, eff↓, ROS↝, Dose↑, other↑,
1777- MEL,    Melatonin as an antioxidant: under promises but over delivers
- Review, NA, NA
*ROS↓, *Fenton↓, *antiOx↑, *toxicity∅, *GPx↑, *GSR↑, *GSH↑, *NO↓, *Iron↓, *Copper↓, *IL1β↓, *iNOS↓, *Casp3↓, *BBB↑, *RenoP↑, chemoP↑, *Ca+2↝, eff↑, *PKCδ?, ChemoSen↑, eff↑, Akt↓, DR5↑, selectivity↑, ROS↑, eff↑,
4705- MEL,    Melatonin: beyond circadian regulation - exploring its diverse physiological roles and therapeutic potential
- Review, Nor, NA
*CLOCK↝, *BMD↑, *cardioP↑, *neuroP↑, *Sleep↑,
995- MEL,    Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma
- vitro+vivo, GBM, NA
LDHA↓, MCT4↓, lactateProd↓, i-pH↓, ROS↑, ATP↓, TumCD↑, TumCCA↑, PDH↓, Glycolysis↓, GlucoseCon↓, TumCG↓,
971- MEL,    Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP
Hif1a↓, VEGF↓, p‑p70S6↓,
1063- MEL,    HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways
- in-vitro, Lung, A549 - in-vitro, Lung, PC9
AntiCan↑, TumCMig↓, GSH↓, Casp3↑, Apoptosis↑, ROS↑, HDAC1↓, Ac-histone H3↑, PUMA↑, BAX↑, PCNA↓, Bcl-2↓,
1042- MEL,    Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H460 - in-vitro, Lung, LLC1
PD-L1↓, YAP/TEAD↓, TAZ↓, TumCG↓,
1066- MET,    Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma
- in-vitro, SCC, NA
PDH↑, Hif1a↓, TumCMig↓, Casp3↑, P53∅,
1043- MET,  immuno,    Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
- in-vitro, NA, NA
eff↑, PD-L1↓, Ki-67↑, TIM-3↑, L-sel↑,
994- MET,    Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy
- in-vitro, Var, NA
Glycolysis↓, HK2↓, ATP↓, AMPK↑, P53↑, Warburg↓, Apoptosis↑,
970- MET,    Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer
CAFs/TAFs↝, p‑AMPK↑, PHDs↑, Hif1a↓, TumCI↓,
1204- MET,    Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
MDA↑, ROS↑, Iron↑, GSH↓, T-SOD↓, Catalase↓, GPx4↓, xCT↓, NRF2↓, HO-1↓,
5803- MET,  carbop,    Metformin, at Concentrations Corresponding to the Treatment of Diabetes, Potentiates the Cytotoxic Effects of Carboplatin in Cultures of Ovarian Cancer Cells
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, SKOV3
eff↑, ChemoSen↑, TumCCA↑,
5795- MET,    Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
- Review, AD, NA - Review, Park, NA - Review, Diabetic, NA
*AntiDiabetic↑, *AMPK↑, *glyC↓, *ROS↓, *cardioP↑, *neuroP↑, *Half-Life↝, *toxicity↝, *BioAv↑, *glucose↓, *AGEs↓, AntiCan↑, Risk↓, TumCP↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, pRB↓, p27↓, mTOR↓, Casp↑, ROS↑, MMP↓, ChemoSen↑, *hepatoP↑, *CRM↑, *Insulin↓,
5796- MET,    Tumor, whole blood, plasma, and tissue concentrations of metformin in lung cancer patients
- Human, Lung, NA
selectivity↑, AMPK↑, Risk↓, Half-Life↝, ChemoSen↑,
5804- MET,  NIV,    Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up.
- Case Report, PC, NA
OS↑, Dose↝,
5800- MET,    Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
- Review, Var, NA
ChemoSen↑, RadioS↑, Imm↑, *AntiDiabetic↑, *AMPK↑, TumCP↓, hepatoP↑, ATP↓, AMP↑, glucoNG↓, ROS↑, compI↓, DNAdam↑, CSCs↓, NP/CIPN↓, chemoP↑, toxicity↓, Trx↓, eff↑, cycD1/CCND1↓, CDK4↓, CDK6↓, cycE/CCNE↓, CDK2↓,
5785- MET,    Metformin improves healthspan and lifespan in mice
- in-vivo, Nor, NA
*AntiDiabetic↑, *AntiAge↑, *toxicity⇅, *CRM↑, *Strength↑, *LDL↓, *AMPK↑, *TAC↑, *ROS↓, *Inflam↓, Risk↓, *cardioP↑, *ALAT↓, *NRF2↑, *SOD2↑, *TrxR1↑, *NQO1↑, *NQO2↑,
2456- MET,    Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer
- in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
GlucoseCon↓, TumCG↓, HK2↓, p‑AMPK↑, TXNIP↓, *toxicity↓,
2457- MET,    Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II
- in-vitro, Lung, Calu-1
HK1↓, HK2↓, GlucoseCon↓, MMP↓, ATP↓,
2493- MET,    Metformin Inhibits Gluconeogenesis by a Redox-Dependent Mechanism In Vivo
- in-vivo, Nor, NA
glucoNG↓, glucose↓,
2436- MET,    Metformin alleviates nickel-induced autophagy and apoptosis via inhibition of hexokinase-2, activating lipocalin-2, in human bronchial epithelial cells
- in-vitro, Nor, BEAS-2B
*HK2↓,
2492- MET,    The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective
- Review, Nor, NA
*glucose↓, *glucoNG↓, *AMPK↑,
2491- MET,    Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
- in-vivo, Nor, NA
*glucoNG↓, *glucose↓, *mitResp↓,
2376- MET,    Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway
- in-vitro, Nor, NA
*Hif1a↓, *EMT↓, *p‑P70S6K↓, *PKM2↓,
2375- MET,    Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling
- in-vitro, GC, SGC-7901
tumCV↓, TumCI↓, TumCMig↓, Apoptosis↑, PARP↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, COX2↓,
2371- MET,    The role of pyruvate kinase M2 in anticancer therapeutic treatments
- Review, Var, NA
ChemoSen↑, PKM2↓, Hif1a↓, EMT↓,
2377- MET,    Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa
EMT↓, P70S6K↓, mTOR↓, PKM2↓, Warburg↓, AMPK↑,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2379- MET,    Down‐regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer
- in-vitro, Bladder, T24/HTB-9 - in-vitro, BC, UMUC3
PKM2↓, p‑STAT3↓, TumCG↓, eff↑, chemoP↑, AMPK↑,
2383- MET,    Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2
- in-vitro, RCC, A498
AMPK↑, TumCP↓, eff↓, eff↑,
2374- MET,    Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions
- in-vitro, BC, MCF-7 - in-vitro, BC, SkBr3 - in-vitro, BC, MDA-MB-231
eff↑, Apoptosis↑, Glycolysis↓, PKM2↓, mTOR↓, PARP↓,
2384- MET,    Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication
- in-vitro, Thyroid, BCPAP - in-vivo, NA, NA - in-vitro, Thyroid, TPC-1
Glycolysis↓, OXPHOS↑, tumCV↓, TumCI↓, TumCMig↓, EMT↓, Apoptosis↑, TumCCA↑, LDHA↓, PKM2↓, IDH1↑, TumCG↓,
2385- MET,    Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model
- in-vitro, AD, H4 - in-vitro, NA, HEK293 - in-vivo, NA, NA - in-vitro, NA, SH-SY5Y
*HK2↓, *PKM2↓, *Dose↝, IKKα↑, memory↑, p‑Hsc70↑, APP↓,
2386- MET,    Mechanisms of metformin inhibiting cancer invasion and migration
- Review, Var, NA
OS↑, AMPK↑, EMT↓, TGF-β↓, mTOR↓, P70S6K↓, PKM2↓, Hif1a↓, ChemoSen↑,
2387- MET,  GEM,    Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis
- in-vitro, CCA, HCC9810
eff↑, tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, PKM2↓, PDHB↓,
2487- metroC,    Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma
- Review, HCC, NA
toxicity↓, toxicity↓, eff↝, angioG↓, CSCs↓, TSP-1↑, Hif1a↓, VEGF↓, eff↑,
2490- metroC,    Durable complete response of hepatocellular carcinoma after metronomic capecitabine
- Case Report, HCC, NA
angioG↓, TumVol↓, Remission↑,
2489- metroC,  capec,    Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma
- Case Report, HCC, NA
Dose↝, OS↑, TumVol↓, AFP↓,
2488- metroC,    Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma
- in-vitro, HCC, HUH7 - in-vivo, HCC, NA
TumCG↓, toxicity↓, OS↑, TSP-1↑, Dose↓, Dose↓,
2486- metroC,  capec,    Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
- Case Report, HCC, NA
OS↑, eff↝, Dose↝, AFP↓, Dose↝, TumVol↓, AFP↓,
2250- MF,  MNPs,    Confronting stem cells with surface-modified magnetic nanoparticles and low-frequency pulsed electromagnetic field
- Review, NA, NA
*Ca+2↑, *Dose↝, *BioAv↓,
2252- MF,  HPT,    Cellular Response to ELF-MF and Heat: Evidence for a Common Involvement of Heat Shock Proteins?
- Review, NA, NA
HSPs∅, *HSPs↑, eff↝, *eff↑, eff↑, eff↓,

Showing Research Papers: 3501 to 3550 of 5875
Prev Page 71 of 118 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5875

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↓, 1,   Catalase↑, 1,   compI↓, 1,   GPx↑, 1,   GPx4↓, 1,   GSH↓, 2,   HK1↓, 1,   HO-1↓, 1,   Iron↑, 1,   MDA↑, 1,   NRF2↓, 1,   OXPHOS↑, 1,   ROS↑, 10,   ROS↝, 1,   SOD↑, 1,   T-SOD↓, 1,   Trx↓, 1,   xCT↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 4,   MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

Ac-histone H3↑, 1,   AMP↑, 1,   AMPK↑, 6,   p‑AMPK↑, 2,   CAIX↑, 1,   glucoNG↓, 2,   glucose↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 4,   HK2↓, 3,   IDH1↑, 1,   lactateProd↓, 1,   LDHA↓, 2,   MCT4↓, 1,   PDH↓, 1,   PDH↑, 1,   PDHB↓, 1,   PKM2↓, 9,   Warburg↓, 3,  

Cell Death ⓘ

Akt↓, 3,   Apoptosis↑, 8,   BAX↑, 2,   Bcl-2↓, 2,   Casp↑, 1,   Casp3↑, 3,   Casp9↑, 1,   DR5↑, 1,   JNK↑, 1,   MAPK↑, 1,   p27↓, 1,   p27↑, 1,   PUMA↑, 1,   TumCD↑, 2,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

p‑p70S6↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,   pRB↓, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

p‑Hsc70↑, 1,   HSPs∅, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   DNArepair↑, 1,   P53↑, 2,   P53∅, 1,   PARP↓, 2,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 3,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 3,   cycE/CCNE↓, 1,   P21↑, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 2,   EMT↓, 5,   HDAC1↓, 1,   IGF-1R↓, 1,   mTOR↓, 5,   P70S6K↓, 2,   PI3K↓, 2,   PTEN↑, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   TAZ↓, 1,   TumCG↓, 6,   TumCG↑, 1,  

Migration ⓘ

APP↓, 1,   CAFs/TAFs↝, 1,   E-cadherin↑, 2,   Ki-67↑, 1,   L-sel↑, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP9↓, 1,   Snail↓, 1,   TGF-β↓, 1,   Treg lymp↓, 1,   TSP-1↑, 2,   TumCI↓, 5,   TumCMig↓, 6,   TumCP↓, 6,   TumMeta↓, 1,   TumMeta↑, 1,   TXNIP↓, 1,   Vim↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 3,   Hif1a↓, 9,   NO↓, 1,   PHDs↑, 1,   VEGF↓, 3,  

Barriers & Transport ⓘ

GLUT1↑, 1,   GLUT3↑, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   COX2↓, 2,   FOXP3↓, 1,   IKKα↑, 1,   IL1β↓, 1,   IL6↓, 2,   IL8↓, 1,   Imm↑, 1,   NF-kB↓, 1,   NK cell↑, 2,   PD-L1↓, 2,   T-Cell↑, 1,   Th1 response↑, 1,   TNF-α↓, 1,   TNF-α↑, 1,  

Cellular Microenvironment ⓘ

i-pH↓, 1,   TIM-3↑, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,   ChemoSen↑, 11,   Dose↓, 2,   Dose↑, 3,   Dose↝, 4,   Dose∅, 2,   eff↓, 3,   eff↑, 17,   eff↝, 3,   Half-Life↝, 1,   RadioS↑, 2,   selectivity↑, 5,  

Clinical Biomarkers ⓘ

AFP↓, 3,   IL6↓, 2,   Ki-67↑, 1,   PD-L1↓, 2,  

Functional Outcomes ⓘ

AntiCan↑, 3,   AntiTum↑, 1,   chemoP↑, 4,   ChemoSideEff↓, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 1,   NP/CIPN↓, 1,   OS↑, 7,   OS∅, 1,   QoL↑, 2,   radioP↑, 2,   Remission↑, 2,   Risk↓, 5,   toxicity↓, 4,   TumVol↓, 4,  
Total Targets: 164

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 2,   Catalase↑, 1,   Copper↓, 1,   Fenton↓, 1,   GPx↑, 2,   GSH↑, 3,   GSR↑, 1,   HO-1↑, 1,   Iron↓, 1,   lipid-P↓, 1,   NQO1↑, 1,   NRF2↑, 2,   ROS↓, 7,   SOD↑, 1,   SOD2↑, 1,   TAC↑, 1,   TrxR1↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 2,   Insulin↓, 1,   mitResp↓, 1,   mitResp↑, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   AMPK↑, 4,   CRM↑, 2,   glucoNG↓, 2,   glucose↓, 3,   glyC↓, 1,   HK2↓, 2,   LDL↓, 1,   PKM2↓, 2,  

Cell Death ⓘ

Casp3↓, 1,   iNOS↓, 1,  

Protein Folding & ER Stress ⓘ

HSPs↑, 1,   NQO2↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CLOCK↝, 1,   EMT↓, 1,   p‑P70S6K↓, 1,  

Migration ⓘ

Ca+2↑, 1,   Ca+2↝, 1,   PKCδ?, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,   NO↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   Inflam↓, 1,   NF-kB↑, 1,  

Protein Aggregation ⓘ

AGEs↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,   Dose↝, 2,   eff↑, 2,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   BMD↑, 1,   NOS2↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   AntiDiabetic↑, 3,   cardioP↑, 3,   CardioT↓, 1,   hepatoP↑, 1,   neuroP↑, 2,   RenoP↑, 1,   Sleep↑, 1,   Strength↑, 1,   toxicity↓, 2,   toxicity⇅, 1,   toxicity↝, 1,   toxicity∅, 2,  
Total Targets: 69

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page